Insights & Resources – COD Research – Designing Therapies For Future

Medical Affairs

CT Quality Assurance

Clinical Services

Biometrics

Transforming Complexity into Success: A Large-Scale Global Phase III Biosimilar Dermatology Trial

Strategic Planning for Patient Recruitment

Pulmonary Disease Introduction: Prevalence, Causes, Prevention & Treatment

EMA
FDA
MHRA

PSUSA/00002047/202412
Source: EMA Published on 2025-07-11
PSUSA/00001013/202411
Source: EMA Published on 2025-07-11
PSUSA/00002257/202412
Source: EMA Published on 2025-07-11
Human medicines European public assessment report (EPAR): Idacio, adalimumab, Date of authorisation: 02/04/2019, Revision: 13, Status: Authorised
Source: EMA Published on 2025-07-11
Human medicines European public assessment report (EPAR): Sugammadex Fresenius Kabi, sugammadex, Date of authorisation: 15/07/2022, Revision: 2, Status: Authorised
Source: EMA Published on 2025-07-11
Human medicines European public assessment report (EPAR): Epoetin Alfa Hexal, epoetin alfa, Date of authorisation: 27/08/2007, Revision: 27, Status: Authorised
Source: EMA Published on 2025-07-11

Read More